Royalty Pharma plc（RPRX）の株価・分析・データ
本質的価値
アナリスト予想
株価予想 →$61,00 – $70,00
中央値 $65,50 · 10.92% 上昇余地
最新決算
| 実績 | 予想との差 | 前年比 | |
|---|---|---|---|
| 売上高 | $674.1M | n/a | +16.50% |
| EPS（TTM） | $1,32 | +$0,05 | +15.79% |
事業指標
Royalty Pharma plcについて
企業情報を見る →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.